BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 31757951)

  • 1. Functional analysis of genetic variants in the high-risk breast cancer susceptibility gene PALB2.
    Boonen RACM; Rodrigue A; Stoepker C; Wiegant WW; Vroling B; Sharma M; Rother MB; Celosse N; Vreeswijk MPG; Couch F; Simard J; Devilee P; Masson JY; van Attikum H
    Nat Commun; 2019 Nov; 10(1):5296. PubMed ID: 31757951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional characterization of 84 PALB2 variants of uncertain significance.
    Wiltshire T; Ducy M; Foo TK; Hu C; Lee KY; Belur Nagaraj A; Rodrigue A; Gomes TT; Simard J; Monteiro ANA; Xia B; Carvalho MA; Masson JY; Couch FJ
    Genet Med; 2020 Mar; 22(3):622-632. PubMed ID: 31636395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Missense PALB2 germline variant disrupts nuclear localization of PALB2 in a patient with breast cancer.
    Toh MR; Low CE; Chong ST; Chan SH; Ishak NDB; Courtney E; Kolinjivadi AM; Rodrigue A; Masson JY; Ngeow J
    Fam Cancer; 2020 Apr; 19(2):123-131. PubMed ID: 32048105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Validated Functional Analysis of Partner and Localizer of BRCA2 Missense Variants for Use in Clinical Variant Interpretation.
    Brnich SE; Arteaga EC; Wang Y; Tan X; Berg JS
    J Mol Diagn; 2021 Jul; 23(7):847-864. PubMed ID: 33964450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional Analysis Identifies Damaging CHEK2 Missense Variants Associated with Increased Cancer Risk.
    Boonen RACM; Wiegant WW; Celosse N; Vroling B; Heijl S; Kote-Jarai Z; Mijuskovic M; Cristea S; Solleveld-Westerink N; van Wezel T; Beerenwinkel N; Eeles R; Devilee P; Vreeswijk MPG; Marra G; van Attikum H
    Cancer Res; 2022 Feb; 82(4):615-631. PubMed ID: 34903604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional Characterization of
    Boonen RACM; Vreeswijk MPG; van Attikum H
    Front Mol Biosci; 2020; 7():169. PubMed ID: 33195396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PALB2 Variants: Protein Domains and Cancer Susceptibility.
    Nepomuceno TC; Carvalho MA; Rodrigue A; Simard J; Masson JY; Monteiro ANA
    Trends Cancer; 2021 Mar; 7(3):188-197. PubMed ID: 33139182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ablation of the Brca1-Palb2 Interaction Phenocopies Fanconi Anemia in Mice.
    Park D; Bergin SM; Jones D; Ru P; Koivisto CS; Jeon YJ; Sizemore GM; Kladney RD; Hadjis A; Shakya R; Ludwig T
    Cancer Res; 2020 Oct; 80(19):4172-4184. PubMed ID: 32732220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterisation of protein-truncating and missense variants in
    Ng PS; Boonen RA; Wijaya E; Chong CE; Sharma M; Knaup S; Mariapun S; Ho WK; Lim J; Yoon SY; Mohd Taib NA; See MH; Li J; Lim SH; Tan EY; Tan BK; Tan SM; Tan VK; van Dam RM; Rahmat K; Yip CH; Carvalho S; Luccarini C; Baynes C; Dunning AM; Antoniou A; van Attikum H; Easton DF; Hartman M; Teo SH
    J Med Genet; 2022 May; 59(5):481-491. PubMed ID: 33811135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Compromised BRCA1-PALB2 interaction is associated with breast cancer risk.
    Foo TK; Tischkowitz M; Simhadri S; Boshari T; Zayed N; Burke KA; Berman SH; Blecua P; Riaz N; Huo Y; Ding YC; Neuhausen SL; Weigelt B; Reis-Filho JS; Foulkes WD; Xia B
    Oncogene; 2017 Jul; 36(29):4161-4170. PubMed ID: 28319063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Germline mutations of PALB2 gene in a sequential series of Chinese patients with breast cancer.
    Zhang K; Zhou J; Zhu X; Luo M; Xu C; Yu J; Deng M; Zheng S; Chen Y
    Breast Cancer Res Treat; 2017 Dec; 166(3):865-873. PubMed ID: 28825143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional evaluation of BRCA2 variants mapping to the PALB2-binding and C-terminal DNA-binding domains using a mouse ES cell-based assay.
    Biswas K; Das R; Eggington JM; Qiao H; North SL; Stauffer S; Burkett SS; Martin BK; Southon E; Sizemore SC; Pruss D; Bowles KR; Roa BB; Hunter N; Tessarollo L; Wenstrup RJ; Byrd RA; Sharan SK
    Hum Mol Genet; 2012 Sep; 21(18):3993-4006. PubMed ID: 22678057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequency of pathogenic germline mutation in CHEK2, PALB2, MRE11, and RAD50 in patients at high risk for hereditary breast cancer.
    Kim H; Cho DY; Choi DH; Oh M; Shin I; Park W; Huh SJ; Nam SJ; Lee JE; Kim SW
    Breast Cancer Res Treat; 2017 Jan; 161(1):95-102. PubMed ID: 27783279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A BRCA1 Coiled-Coil Domain Variant Disrupting PALB2 Interaction Promotes the Development of Mammary Tumors and Confers a Targetable Defect in Homologous Recombination Repair.
    Pulver EM; Mukherjee C; van de Kamp G; Roobol SJ; Rother MB; van der Gulden H; de Bruijn R; Lattanzio MV; van der Burg E; Drenth AP; Verkaik NS; Hahn K; Klarenbeek S; de Korte-Grimmerink R; van de Ven M; Pritchard CEJ; Huijbers IJ; Xia B; van Gent DC; Essers J; van Attikum H; Ray Chaudhuri A; Bouwman P; Jonkers J
    Cancer Res; 2021 Dec; 81(24):6171-6182. PubMed ID: 34548335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional Categorization of
    Bouwman P; van der Heijden I; van der Gulden H; de Bruijn R; Braspenning ME; Moghadasi S; Wessels LFA; ; Vreeswijk MPG; Jonkers J
    Clin Cancer Res; 2020 Sep; 26(17):4559-4568. PubMed ID: 32546644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutation status of RAD51C, PALB2 and BRIP1 in 100 Japanese familial breast cancer cases without BRCA1 and BRCA2 mutations.
    Sato K; Koyasu M; Nomura S; Sato Y; Kita M; Ashihara Y; Adachi Y; Ohno S; Iwase T; Kitagawa D; Nakashima E; Yoshida R; Miki Y; Arai M
    Cancer Sci; 2017 Nov; 108(11):2287-2294. PubMed ID: 28796317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence and spectrum of germline rare variants in BRCA1/2 and PALB2 among breast cancer cases in Sarawak, Malaysia.
    Yang XR; Devi BCR; Sung H; Guida J; Mucaki EJ; Xiao Y; Best A; Garland L; Xie Y; Hu N; Rodriguez-Herrera M; Wang C; Jones K; Luo W; Hicks B; Tang TS; Moitra K; Rogan PK; Dean M
    Breast Cancer Res Treat; 2017 Oct; 165(3):687-697. PubMed ID: 28664506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Splicing predictions, minigene analyses, and ACMG-AMP clinical classification of 42 germline PALB2 splice-site variants.
    Valenzuela-Palomo A; Bueno-Martínez E; Sanoguera-Miralles L; Lorca V; Fraile-Bethencourt E; Esteban-Sánchez A; Gómez-Barrero S; Carvalho S; Allen J; García-Álvarez A; Pérez-Segura P; Dorling L; Easton DF; Devilee P; Vreeswijk MP; de la Hoya M; Velasco EA
    J Pathol; 2022 Mar; 256(3):321-334. PubMed ID: 34846068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer.
    Weitzel JN; Neuhausen SL; Adamson A; Tao S; Ricker C; Maoz A; Rosenblatt M; Nehoray B; Sand S; Steele L; Unzeitig G; Feldman N; Blanco AM; Hu D; Huntsman S; Castillo D; Haiman C; Slavin T; Ziv E
    Cancer; 2019 Aug; 125(16):2829-2836. PubMed ID: 31206626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rare, protein-truncating variants in
    Decker B; Allen J; Luccarini C; Pooley KA; Shah M; Bolla MK; Wang Q; Ahmed S; Baynes C; Conroy DM; Brown J; Luben R; Ostrander EA; Pharoah PD; Dunning AM; Easton DF
    J Med Genet; 2017 Nov; 54(11):732-741. PubMed ID: 28779002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.